PB-CD19-CAR T-cell therapy (MaxCyte)

N/A

Report date: 2025/01/26 15:14:30

Base Information

Drug NamePB-CD19-CAR T-cell therapy (MaxCyte)

Drug Alias NameAnti-CD19 CAR T-cell therapy (MaxCyte)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMaxcyte Inc

China Registration ClassN/A

Develop Information

Active CompaniesMaxcyte Inc

Inactive CompaniesN/A

Active IndicationsLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A